Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07940369
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-07940369 is an investigational small molecule drug developed by Pfizer. It is being studied as a new chemical entity for the treatment of anemia of clonal hematopoiesis (ACH). The drug is administered orally, typically in solution form. As of early 2025, its mechanism of action has not been publicly disclosed. Clinical development is currently in Phase 1, with ongoing studies evaluating its safety, tolerability, and pharmacokinetics in healthy adult participants[2][3][7].
Beyond the preview
Go deeper on PF-07940369.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07940369.